Angiogenesis associates with poor outcome in diffuse large B-cell lymphoma (DLBCL), but the contribution of the lymphoma cells to this process remains unclear. Addressing this knowledge gap may uncover unsuspecting proangiogenic signaling nodes and highlight alternative antiangiogenic therapies. Here, we identify the second messenger cyclic-AMP (cAMP) and the enzyme that terminates its activity, phosphodiesterase 4B (PDE4B), as regulators of B-cell lymphoma angiogenesis. We first show that cAMP, in a PDE4B-dependent manner, suppresses PI3K/AKT signals to downmodulate vascular endothelial growth factor (VEGF) secretion and vessel formation in vitro. Next, we create a novel mouse model that combines the lymphomagenic Myc transgene with germline deletion of Pde4b. We show that lymphomas developing in a Pde4b-null background display significantly lower microvessel density (MVD) in association with lower VEGF levels and PI3K/AKT activity. We recapitulate these observations by treating lymphomabearing mice with the FDA-approved PDE4 inhibitor, Roflumilast. Lastly, we show that primary human DLBCLs with high PDE4B expression display significantly higher MVD. Here, we defined an unsuspected signaling circuitry in which the cAMP generated in lymphoma cells downmodulates PI3K/AKT and VEGF secretion to negatively influence vessel development in the microenvironment. These data identify PDE4 as an actionable antiangiogenic target in DLBCL.
INTRODUCTION
Angiogenesis, the development of new blood vessels from preexisting vasculature, results from the production of proangiogenic factors by cancer and nonmalignant cells in the tumor microenvironment. 1 This abnormal vascular network is critical for the tumor metabolism and for its metastatic potential. 2 Thus, the concept of targeting the tumor blood supply, primarily with agents that directly inhibit vascular endothelial growth factor (VEGF) signals, has been incorporated in cancer treatment. 1, 2 These antiangiogenic strategies have improved clinical response in some settings, but the benefits are often modest and of limited impact on overall survival. 1, 2 Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous malignancy derived from mature B cells. 3 Examination of the transcriptional and genetic landscape of DLBCL identified gene signatures associated with outcome and mechanisms of transformation, [4] [5] [6] and uncovered the contribution of chromatin regulators to the disease biology. 7 However, this knowledge has yet to be translated into effective rationally-developed treatment strategies, and first-line immunochemotherapy (R-CHOP) remains curative for only about 60% of the DLBCL patients. 3 Recognizing and acquiring basic biology data in specific priority areas may accelerate clinical translation in DLBCL. 8 One such knowledge gap concerns the interplay between lymphoma cells, the microenvironment and angiogenesis. Addressing this problem is particularly important because high circulating levels of VEGF and increased microvessel density (MVD) in the lymphoma microenvironment are associated with poor outcome in DLBCL. 5, [9] [10] [11] [12] Unfortunately, the combination of anti-VEGFA agents with R-CHOP was associated with prohibitive cardiotoxicity and did not improve survival. 13, 14 Thus, a better understanding of the contribution of the lymphoma cell to angiogenesis also has the potential to identify alternative antiangiogenic therapeutic strategies in DLBCL.
Cyclic-AMP (cAMP) is a pervasive second messenger that in immune cells exerts predominantly negative effects, including the suppression of B-or T-cell receptor signaling, modulation of cytokine production and apoptosis. [15] [16] [17] [18] [19] Intracellular cAMP signaling is terminated by phosphodiesterases, and in immune cells, the phosphodiesterase 4 (PDE4) family catalyze most of the cAMP hydrolysis. 20 Earlier, we identified PDE4B overexpression in an outcome prediction signature in DLBCL. 21 Subsequently, we showed that PDE4B contributes to DLBCL aggressiveness by abrogating the cAMP-mediated inhibition of PI3K/AKT and SYK signaling. 17, 18, 22 The consequences of cAMP activity are highly contextualized and cell type-specific. 19, 20 Thus, it is of interest that cAMP has been shown to attenuate vessel development in nonneoplastic cell models, at least in part by acting on endothelial 1 cells. [23] [24] [25] [26] However, whether cAMP can influence the secretion of proangiogenic factors by lymphoma cells and thus modulate the cross talk between tumor and microenvironment remains to be determined.
To examine this possibility, we developed in vitro systems, generated a novel mouse and studied primary DLBCL samples. In DLBCL cell lines, we show that cAMP downmodulates VEGF transcription/secretion and vessel formation in a PDE4B-dependent manner. DLBCL cell lines expressing high levels of PDE4B have a proangiogenic profile that can be suppressed by genetically or pharmacologically inhibiting PDE4. Mechanistically, we show that the cAMP-PDE4B axis impinges on VEGF by modulating PI3K and AKT signals. We also created a mouse model where c-Myc-driven lymphoma develops in a Pde4b − / − background. Remarkably, Pde4b-null B-cell lymphomas displayed significantly suppressed angiogenesis, an effect that could be recapitulated by treating Pde4b-competent murine B-cell lymphoma with the FDA-approved PDE4 inhibitor Roflumilast. Examination of the B-cell lymphomas harvested from these in vivo models confirmed that PDE4B influences VEGF levels via the PI3K/AKT pathway. Lastly, we showed that PDE4B expression positively correlates with angiogenesis in primary DLBCL biopsies. Together, these data uncovered a previously unappreciated cAMP-mediated signaling cross talk between the lymphoma cells and the microenvironment that regulates angiogenesis in vivo, and point to PDE4 inhibition as an antiangiogenic therapeutic strategy for DLBCL and related mature B-cell tumors.
MATERIALS AND METHODS
See Supplementary Data for detailed methodology.
Cell lines and primary DLBCL DLBCL cell lines (SU-DHL4, SU-DHL6, SU-DHL10, OCI-Ly4, OCI-Ly10 and OCI-Ly18) were cultured as we described. 27 Paired paraffin blocks and RNA were available from 28 untreated DLBCL patients. The use of these anonymized samples was approved by the Institutional Review Board of the UT Health Science Center San Antonio (UTHSCSA).
Mice
To generate the compound Pde4b − / − ; Eμ-Myc-Tg mice, Pde4b+/ − females 28 were bred to Eμ-Myc-Tg males. Subsequently, Pde4b+/ − females were crossed to Pde4b+/ − ;Myc-Tg males, creating the desired Pde4b − / − ; Eμ-Myc-Tg strain and control Pde4b+/+;Eμ-Myc-Tg mice. For the adoptive transfer assays, C57BL/6 mice were transplanted with Eμ-Myc-Tg-derived lymphoma cells and randomized to receive the PDE4 inhibitor Roflumilast or vehicle control. All procedures were approved by the IACUC of the UTHSCSA.
VEGF and cAMP quantification VEGFA abundance was examined at RNA and protein levels, in human and murine samples, using real-time RT-PCR 29 and the Human or Mouse VEGF Immunoassay (R&D Systems, Minneapolis, MN, USA), respectively. Intracellular and extracellular (conditioned media) cAMP levels were measured using ELISA (Parameter cAMP assay; R&D Systems).
Tube formation assay
The tube formation assay was performed on low passage sub-confluent human umbilical vein endothelial cells (HUVEC, Life Technologies, Carlsbad, CA, USA) using conditioned media from DLBCL cell lines.
PI3K assay
Quantification of PI3K activity was performed on whole-cell lysates collected from DLBCL cell lines or primary murine lymphomas, utilizing an ELISA-based assay (Echelon Biosciences, Salt Lake City, UT, USA).
Genetic models and western blots DLBCL cell lines stably expressing PDE4B and AKT constructs or with siRNAmediated PDE4B KD were described earlier. 17, 18, 22 Western blots for PDE4B, AKT, FLAG and Actin were performed as we described. 30 
Histopathology
Slides stained for CD34 were digitally scanned and examined in a blinded manner for MVD quantification using Aperio ImageScope software (Leica Biosystems, Buffalo Grove, IL, USA). For each case, three hot spots (area of maximal MVD) were examined and all microvessels were manually counted and highlighted using the ImageScope software, which calculated the area of each vessel.
Statistics
Analyses performed with GraphPad Prism5 software included two-tailed Student's t-test, one-way analysis of variance, Spearman's rank correlation coefficient, and log-rank test. Po0.05 was considered significant.
RESULTS
cAMP-PDE4B-mediated modulation of VEGFA in DLBCL Using a panel of DLBCL cell lines dichotomized by PDE4B expression/activity (Supplementary Figure 1) , we investigated whether the cAMP-PDE4B axis influenced VEGFA levels. Increasing intracellular cAMP (via pharmacologic activation of adenylyl cyclases with Forskolin) suppressed VEGFA mRNA levels in PDE4B-low but not in PDE4B-high cells (Figure 1a ). In agreement with the mRNA data, cAMP inhibited VEGF secretion in the conditioned media of the DLBCL cell lines in a PDE4B-dependent manner (Figure 1b) . The cAMP analog 8-Br-cAMP confirmed that the suppression of VEGF in DLBCL cell lines exposed to Forskolin derived from elevation of cAMP levels (Supplementary Figure 2) . Using HUVEC tube formation assays, we show that cAMP inhibited the vessel formation capability of conditioned media from PDE4B-low, but not PDE4B-high DLBCL cells (Figure 1c) . Importantly, because cAMP can directly inhibit endothelial cells, 25, 26 we established several safeguards to guarantee that the HUVEC assays are reflective of the effects of cAMP on the production of VEGF by the lymphoma cells, and not from the fortuitous presence of Forskolin and/or cAMP in the conditioned media (see Supplementary Methods and Supplementary Figure 3) . We concluded that in DLBCL cell lines, cAMP suppresses VEGF levels and in vitro vessel development in a PDE4B-dependent manner.
Genetic and pharmacological approaches confirm the role of PDE4B in regulating cAMP-mediated VEGF suppression To isolate the role of PDE4B in the cAMP/VEGF interplay, we used genetic and pharmacological approaches. First, we stably expressed PDE4B wild-type (WT) or phosphodiesterase-inactive mutant genes in a PDE4B-low DLBCL cell line. Expression of WT PDE4B abrogated the suppressive effects of cAMP on VEGF secretion and HUVEC tube formation, whereas the mutant phosphodiesterase was as ineffective as the empty vector (Figure 2a) . Using a siRNA strategy in a PDE4B-high cell line, we showed that PDE4B knockdown significantly suppressed VEGF secretion and tube formation (Figure 2b, Supplementary Figure 4) . Lastly, in multiple PDE4B-high DLBCLs, exposure to the PDE4 inhibitor Roflumilast resulted in a significant decrease in VEGF secretion, which was accompanied by reduced tube formation capacity (Figure 2c ). We concluded that PDE4B regulates cAMPmediated suppression of VEGF in DLBCL, suggesting that the levels/activity of PDE4B in lymphoma cells may influence angiogenesis in the tumor microenvironment.
The PDE4B-cAMP axis influences VEGF expression by modulating PI3K/AKT signals We investigated whether the cAMP-mediated/PDE4B-dependent modulation of VEGF expression in DLBCL was related to the suppression of PI3K/AKT that we reported earlier. 18 cAMP significantly suppressed PI3K activity in PDE4B-low but not in PDE4B-high DLBCL cell lines (Figure 3a) . Further, ectopic expression of WT PDE4B, but not the inactive enzyme, blocked cAMP suppression of PI3K (Figure 3b ). AKT has a crucial role in the regulation of VEGF under normoxic conditions. 31 Thus, we reasoned that downstream to PI3K, cAMP-PDE4B uses AKT to regulate VEGF. Indeed, phosphorylation of AKT's threonine 308 was markedly suppressed by cAMP in the cells expressing low, but not high PDE4B levels and rescued by the WT but not the inactive enzyme (Figure 3c ). Lastly, we expressed a myristoylated form of AKT in PDE4B-low cells and re-examined the effects of cAMP on PI3K activity, VEGF secretion and tube formation. As PI3K is upstream to AKT, even in the context of a constitutively active AKT, cAMP readily suppressed this lipid kinase activity (Figure 3d ). However, in these cells, cAMP did not suppress AKT, VEGF secretion and the development of vessel-like structures ( Figure 3d ). We concluded that in DLBCL cell lines, cAMP-PDE4B modulates VEGF and angiogenesis via the PI3K/AKT pathway.
Genetic deletion of Pde4b limits angiogenesis in vivo
To advance the concept that PDE4B controls angiogenesis in B-cell lymphoma, we generated a novel compound mouse that combines the lymphomagenic Myc transgene with homozygous deletion of the Pde4b gene (Pde4b − / − ;Eμ-Myc-Tg). Although the Eμ-Myc mice develop B-cell lymphomas with variable degrees of maturation, 32 its dependence on c-myc and on secondary hits on p53 and BCL-2 recapitulates in part the biology of mature B-cell lymphomas. 33 For these reasons, as well as its high penetrance and short latency, this mouse has been instrumental in the identification of lymphomagenic processes and response to targeted agents. [34] [35] [36] [37] [38] The Pde4b − / − ;Eμ-Myc-Tg mice and their Pde4b+/+;Eμ-Myc-Tg counterparts were followed clinically for evidence of lymphoma (see Supplementary Table 1 for features of lymphomas developed in Pde4b+/+ or Pde4b − / − mice). Upon tumor diagnosis, the mice (n = 19) were killed and lymphomas collected for histological characterization and immunohistochemistrybased quantification of angiogenesis with anti-CD34 staining. Remarkably, lymphomas that developed in a Pde4b-null background displayed significantly lower MVD (Figure 4a ). In addition, Pde4b − / − primary lymphomas showed lower PI3K activity, phospho-AKT levels ( Figure 4b ) and VEGF expression than tumors that developed in the Pde4b-WT mice (Figure 4c ). We concluded Conditioned media from PDE4B-low DLBCL cell lines exposed to Forskolin were significantly less efficient in promoting tube formation, whereas no changes were detectable in DLBCL cell lines expressing high PDE4B (Po0.05, two-tailed Student's t-test for each measure in PDE4B-low cell lines; nonsignificant in the PDE4B-high). Data shown are the mean ± s.d. of two independent biological replicates, each performed in triplicate. Note that the conditioned media used in (b) and (c) do not contain Forskolin; this drug was washed-off from the culture 24 h before supernatant collection.
that the Pde4b/Pi3k/Akt/Vegf axis is active in vivo, that the genetic deletion of Pde4b suppresses VEGF expression in the tumor cells and that it inhibits angiogenesis in the microenvironment of primary murine B-cell lymphomas.
Pharmacological targeting of Pde4 limits angiogenesis and improves survival in a murine model of B-cell lymphoma The data obtained in the mice described above were very informative and reinforced the concept that Pde4b expression modulates angiogenesis in B-cell lymphomas. However, in this model, Pde4b is deleted in the germline, thus not fully recapitulating the clinical use of PDE4 inhibitors. To address this concern, we used adoptive transfer and treated lymphomaharboring mice with the PDE4 inhibitor Roflumilast. We generated four independent mouse cohorts (n = 68), each derived from a unique Eμ-Myc-Tg B-cell lymphoma. In the first two groups (n = 16), tumors developed at day 10 post transplant and the mice were randomized to receive Roflumilast (5 mg/kg/day by gavage) or vehicle control; after 5 days of treatment, all mice were killed and tumors collected for MVD quantification. Lymphomas from Roflumilast-treated mice displayed a significantly lower vessel density than tumors that developed in vehicle-treated mice (Figure 5a ). To link the antiangiogenic effects of PDE4 inhibition to the suppression of VEGF, we transplanted a third cohort of mice (n = 8), randomized them into Roflumilast or vehicle control. This time, in addition to lymph nodes for histopathology and immunohistochemistry, we also collected sera for VEGF quantification. We confirmed that Roflumilast treatment significantly decreased MVD and showed that this effect was associated with significantly lower levels of circulating VEGF (Figure 5b ). In these three independent cohorts (n = 24 mice), the lymphomas displayed an aggressive behavior and because we waited until day 10 post transplant to randomize the mice, they were uniformly killed with progressive disease 5 days into treatment. To address the limitations associated with this short clinical follow-up, we tested dosing Roflumilast on day 5 post transplant, before clinical evidence of lymphoma. In a pilot assay (n = 8), mice receiving prophylactic Roflumilast had a significant decrease in lymphoma-associated MVD and circulating VEGF (Supplementary Figure 5) , and also a modest improvement in survival. We then designed an experiment with enough power to test the hypothesis that in association with suppression of angiogenesis, Pde4 inhibition may limit lymphoma growth and improve survival. We transplanted a cohort of 36 mice and randomized them on day 5 into vehicle or Roflumilast groups; mice were followed clinically and killed when there was evidence of widespread disease or at treatment day 30, whichever came first. At the completion of the experiment, the median survival of the Roflumilast-treated mice had not yet been reached and it was 23 days for the vehicle-treated group (P = 0.01, log-rank test); 10 mice in the Roflumilast group and 2 mice in the vehicle-treated , but it blocked the effects of this second messenger on AKT phosphorylation (T308), VEGF secretion (middle graph) and HUVEC tube formation (right side graph). Representative tube formation images are shown at the bottom. Note that the conditioned media used in these assays do not contain Forskolin, this drug was washed off from the culture 24 h before supernatant collection. The PIP3 data are mean ± s.d. of an assay performed in triplicate (P-values are two-tailed Student's t-test). The data were validated with two biological replicates. The VEGF secretion and tube formation assays are mean ± s.d. of three independent biological replicates (P-values are two-tailed Student's t-test for each measure in each cell model).
group were alive at the time the assay was terminated (Figure 5c ). Further, lymphomas that arose in the Roflumilast-treated mice were significantly smaller than the isogenic tumors that developed in the control group (Figure 5c ), and displayed significantly lower PI3K activity, AKT phosphorylation and VEGF levels than the control group (Figure 5d ). We concluded that pharmacological inhibition of PDE4 suppresses lymphoma angiogenesis in vivo, in association with reduced PI3K/AKT activity and VEGF levels. This profile is accompanied by a decreased tumor burden and improved survival, suggesting that PDE4 inhibitors have antilymphoma activity.
PDE4B expression correlates with angiogenesis in primary human DLBCL To further define the relevance of our in vitro and in vivo data, we tested whether PDE4B expression correlates with angiogenesis in primary human DLBCLs. Paired paraffin blocks and RNA were available from 28 untreated DLBCL cases. 39, 40 Anti-CD34 staining was used to identify the MVD in these primary DLBCL and Q-RT-PCR was used for the quantification of PDE4B expression. The latter was selected as the approach of choice because multiple attempts to establish immunohistochemical staining for PDE4B with available antibodies were unsuccessful, and good quality protein from these specimens were not available for western blot-based examinations. Importantly, as we showed before 18 (and in Supplementary Figure 1) there is a very good correlation between PDE4B mRNA and protein expression indicating that this Q-RT-PCR assay captures relevant information. In agreement with earlier observations, 5, 11, 12, 41, 42 we found a significant variability in The log-rank test showed a significantly improved survival rate in the Roflumilasttreated mice (n = 36, P = 0.01). Bottom graph-lymphomas excised from Roflumilast-treated mice were significantly smaller than those derived from mice treated with a vehicle control (P o0.0001, two-tailed Student's t-test, n = 33). Representative examples of lymphomas collected from these mice are shown on the right. (d) Circulating levels of VEGFA and tumoral PI3K activity (top and bottom graphs, respectively) were significantly lower in mice randomized to receive Roflumilast than in vehicle control-treated mice (P = 0.04 and P o0.0001, respectively, two sided Student's t-test). Data shown are mean ± s.e.m. of 30 mice and 28 tumors, respectively; PIP3 levels were measured in triplicates. Right panel-western blot examination of primary murine B-cell lymphomas indicate that AKT phosphorylation (T308) is significantly suppressed following Roflumilast administration (P = 0.003, two-tailed Student's t-test-densitometric pAKT values, normalized by totaL AKT, n = 22).
the degree of angiogenesis in the microenvironment of DLBCLs. Likewise, as we defined earlier, 18 there was a broad range of PDE4B expression across the DLBCL biopsies (Supplementary Figure 6 ). Yet, we detected a significant direct correlation between PDE4B levels and MVD in DLBCL (r = 0.43, P = 0.02) ( Figure 6 ). These data are particularly relevant for they derive from unmodified and heterogeneous primary human tumors, in which a given phenotype (for example, angiogenesis) is likely to be influenced by multiple genetic inputs. Together, these observations agree with our in vitro and mouse model data, and suggest that PDE4B expression may contribute to angiogenesis in human DLBCL.
DISCUSSION
Exacerbated angiogenesis associates with poor outcome in DLBCL. 5, 9, 11, 14 However, little is known about the contribution of the lymphoma cells to this process. Here, we detail a novel role for the second messenger cAMP and the enzyme PDE4B in regulating new vessel development in B-cell lymphoma. Further, using a FDA-approved PDE4 inhibitor, we demonstrate the immediate translational potential of this discovery.
The interplay between lymphoma cells, the microenvironment and angiogenesis remains poorly understood. 5, 11 Our data show that the expression and activity of PDE4B in DLBCL cell lines and in primary murine B-cell lymphomas regulate VEGF secretion in the microenvironment and angiogenesis. The identification of PDE4B overexpression in a gene signature associated with poor outcome in DLBCL established the first link between this enzyme and B-cell lymphomas. 21 Subsequently, we showed that in normal and malignant mature B cells, cAMP markedly suppresses the activity of kinases important to proximal B-cell receptor signaling, in particular SYK and PI3K. 17, 18 As phosphodiesterases hydrolyze cAMP, DLBCL cells with elevated PDE4B expression display heightened SYK and PI3K activity, which may in part explain how it could influence lymphoma aggressiveness. The data that we report now establish angiogenesis as a novel paradigm for PDE4B contribution to an adverse outcome in DLBCL. Notably, despite some discordant reporting, the role of angiogenesis to DLBCL outcome appears to be independent from the germinal center B-cell-and activated B-cell-like dichotomy. 5, 11, 41 Similarly, the expression of PDE4B in primary DLBCL and DLBCL cell lines is independent of the cell-of-origin classifier. 6, 17, 18 We expanded on our in vitro observations by creating a mouse that combines a lymphoma-driving allele (Eμ-Myc) with homozygous deletion of Pde4b. B-cell lymphomas that developed in these mice showed significantly diminished angiogenesis. PDE4 is an actionable target and we recapitulated the effects of the genetic deletion of Pde4b on angiogenesis by treating mice harboring B-cell lymphomas with Roflumilast. These observations are relevant at several levels. First, with the recognized role of VEGF/angiogenesis in DLBCL outcome, [9] [10] [11] but the prohibitive toxicity of bevacizumab in DLBCL patients, 13, 14 Roflumilast presents an attractive, biologically sound, therapeutic strategy to inhibit lymphoma angiogenesis. Second, because Roflumilast is FDA-approved, its effects on DLBCL angiogenesis in humans can be promptly tested. Of note, we recently activated a small Phase 0/I trial of Roflumilast in patients with advanced mature B-cell malignancies (clinical trial# NCT01888952) and the results of this trial will be relevant in designing new initiatives centered on antiangiogenesis. Third, although we clearly isolated the contribution of PDE4B to B-cell lymphoma angiogenesis, other members of the PDE4 family, notably PDE4D, are also expressed in lymphocytes. 43 Thus, the use of a pan-PDE4 inhibitor such as Roflumilast may actually be beneficial in this setting. Lastly, although the outcome of cAMP signaling and the pattern of phosphodiesterase expression are tissue-specific, it will be important to define in future studies whether PDE4 inhibition also downmodulates angiogenesis in malignancies other than lymphomas. The suggestions that PDE4 targeting may have a place in the treatment of highly vascularized brain tumors and colon cancer 44, 45 provide rationale for implementing these investigations.
cAMP is also known to negatively influence the ability of endothelial cells to migrate, adhere and survive during angiogenesis. 25, 26 Thus, it is possible that in the mouse model that we created, the constitutive homozygous deletion of Pde4b inhibits angiogenesis both via the suppression of VEGF secretion by the lymphomas cells and perhaps also by directly impacting on the endothelial cells. Although this may occur in this model, our data demonstrate an unequivocal contribution of lymphoma cells in the control of angiogenesis. In brief, using immunohistochemical staining of murine B-cell lymphomas, we identified the tumor cells as the main source of VEGF, and demonstrate that its expression is suppressed in the lymphoma developing in a Pde4b-null background. Also, in in vitro models, where DLBCL are cultured in the absence of endothelial cells, we demonstrated that the cAMP-mediated/PDE4B-dependent decrease in VEGF secretion limits the subsequent formation of vessel-like structures by HUVECs. Importantly, we recapitulated the suppression of lymphoma angiogenesis detected in the genetically engineered Pde4b-null mouse with Roflumilast in vivo. Thus, using a pharmacological approach that closely approximates a clinical initiative in humans, we effectively suppressed lymphoma angiogenesis. For these reasons, the precise mapping of the relative contribution of PDE4 inhibition on lymphoma versus endothelial cells becomes, at this juncture, less critical. We suggest that the effectiveness of Roflumilast in our in vivo model mitigates concerns that the constitutive deletion of Pde4b in the mice germline had other unappreciated effects that significantly contributed to the suppression of B-cell lymphoma angiogenesis.
Curiously, whereas treatment with Roflumilast and the knockout of the Pde4b gene in the mouse germline equally inhibited lymphoma angiogenesis, only the former modified the natural history of the Myc-driven B-cell lymphomas. In fact, although Roflumilast-treated mice had lower tumor burden and lived longer, the survival of Eμ-Myc mice was similar irrespective of Pde4b status (Supplementary Table 1 ). The precise reasons for these discrepancies are not immediately clear, but a few possibilities exist. In addition to its role in lymphoma and endothelial cell biology, as discussed above, Pde4b inhibition also suppresses the inflammatory response, as well as several aspects of the innate and acquired immune response. 15, 16, 28, 46 Thus, it could be speculated that deletion of this gene in the germline constitutively limits the activity of multiple cellular components involved in tumor surveillance, which in a prooncogenic context (for example, Eμ-Myc transgene) may contribute to tumor emergence and maintenance. Alternatively, the improved survival of mice harboring Myc-driven B-cell lymphomas treated with Roflumilast may relate to its ability to inhibit not only PDE4B but also the other members of the PDE4 family of phosphodiesterases, as we highlighted above. Irrespective of the reason(s) for the discrepancy between the genetic and pharmacological models that we explored in this work, these results should be viewed with the realization that it is the successful pharmacological inhibition of PDE4, which we achieve in the preclinical murine models, not the genetic modulation of PDE4B levels that will be translated into clinic initiatives. In future work, the generation of mouse models with conditional deletion of Pde4b and/or other Pde4 genes in mature B cells, alongside the use lymphomagenic drivers other than Myc, should help parse out the relative contribution of depleting individual PDE4 genes in different cell types on lymphoma development and progression.
Mechanistically, our data implicated the PI3K/AKT pathway as mediator of the cAMP-PDE4B effects on VEGF. These observations uncovered an additional paradigm for how cAMP may attenuate vessel development in non-neoplastic and neoplastic tissues. [23] [24] [25] [26] 47 Perhaps more importantly, uncovering the participation of PI3K/AKT on the PDE4B-mediated regulation of lymphoma angiogenesis highlights additional translational opportunities. In this context, the recent clinical success of PI3Kδ inhibitors for the treatment of mature B-cell malignancies is noteworthy, 48 for our data suggest that antiangiogenesis may be another putative mechanism for the clinical activity of these agents.
Recently, the contrast between abolishing blood supply versus normalizing tumor vasculature has come to the forefront in the angiogenesis field. The former, which derives from intensive and continuous use of agents that directly target VEGF and its receptors, creates a hypoxic environment that may result in the emergence of aggressive tumor subpopulations resistant to treatment and with heightened metastatic potential.
1,2 Conversely, maneuvers that aim to restore tumor vasculature, primarily by deliberately using a less-intensive administration of anti-VEGF signaling agents, appear to actually establish a microenvironment that improves the efficacy of chemotherapy, radiotherapy and immunotherapy. 2 We have not yet directly probed whether PDE4 inhibition will result in the destruction of blood vessels or a more nuanced normalization of tumor vasculature. However, as PDE4 inhibitors do not directly target VEGF signals on the endothelium, and instead impinge on the vasculature by primarily acting on the lymphoma cells, we suggest that this maneuver is more likely to mimic the low dose approach of anti-VEGF/R therapy, which appears to primarily increase blood perfusion.
1,2 Paradoxically, the significant but not overwhelming decrease in MVD that we detected in mice treated with Roflumilast may represent this concept, especially because this was accompanied by a marked decrease in tumor burden and improved survival.
In summary, we identified a novel cross talk between lymphoma cells and the microenvironment that influences angiogenesis. These data highlighted an unexpected role for the ubiquitous second messenger, cAMP, in controlling tumor angiogenesis, and uncovered unique opportunities for therapeutic intervention in this setting with the use of PDE4 inhibitors. The discovery of PI3K and AKT as mediators of cAMP-PDE4B effects towards VEGF expands the panel of actionable targets that may have antiangiogenic activities in DLBCL. Considering its model of action, there is a possibility that PDE4 inhibition instead of promoting blood vessel destruction would rather induce normalization of tumor vasculature, and hence yield better clinical outcomes than traditional anti-VEGF strategies.
